SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-22-018962
Filing Date
2022-09-28
Accepted
2022-09-28 16:11:42
Documents
6
Period of Report
2022-11-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A eypt_def_14a_09-28-2022.htm DEF 14A 1067751
2 GRAPHIC img230392323_0.jpg GRAPHIC 41162
3 GRAPHIC img230392323_1.jpg GRAPHIC 28889
4 GRAPHIC img230392323_2.jpg GRAPHIC 41162
5 GRAPHIC img230392323_3.jpg GRAPHIC 74103
6 GRAPHIC img230392323_4.jpg GRAPHIC 82125
  Complete submission text file 0000950170-22-018962.txt   1437621
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-51122 | Film No.: 221276206
SIC: 3826 Laboratory Analytical Instruments
Industrial Applications and Services